(via NewsDirect)
hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion.
hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin increase from 18.7% to 23.3%, surpassing prior guidance. The company's absolute EBITDA rose to £30 million, a 44% increase from the previous year.
Khan attributed the success to hVIVO conducting more human challenge trials, leading to improved patient recruitment efficiency and better utilisation of facilities and staff. Despite challenges such as MHRA delays, significant funding for a new
For 2024, the company anticipates hitting a £62 million revenue target, with £180 million in the weighted order book ensuring a robust pipeline. Despite a study cancellation, hVIVO remains confident in its revenue and EBIT margin targets.
Looking forward, hVIVO aims for a £100 million revenue target by 2028, driven by expanding its human challenge trials, increasing clinical trial services, and exploring M&A activities, supported by a strong cash reserve.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source